Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-05-02

Clinical Trial Update: A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Rituximab (MabThera) in chronic lymphocytic leukemia has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MabThera (rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Lymphocytic Leukemia, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2016-05-02